Abstract Poster Wall

2023 Kidney Cancer Research Summit

Abstract 33

Phosphorylation of TRAP1 by the tyrosine kinase c-Abl drives prosurvival signaling in renal cell carcinoma

Mark R. Woodford

Abstract 35

Using Light to Improve the Diagnosis and Treatment of Patients with Kidney Cancer

Michael Walsh

Abstract 36

Nucleotide excision repair deficiency is a hypoxia regulated, targetable therapeutic vulnerability in clear cell renal cell carcinoma

Zoltan Szallasi

Abstract 38

A novel combination treatment to prevent c-Met-induced and Rubicon-Nrf-2-mediated therapeutic resistance in renal cancer

Laxminarayan Rawat

Abstract 41

Creation and implementation of an institutional workflow for systematic collection of fresh renal cell carcinoma tumor biospecimens for investigative studies

Katherine E Sadak


Abstract 42

Development of an experimental toolkit to assess T cell function in renal cell carcinoma (RCC)

Hanna A. Soulati, Soki Kashima

Abstract 43

SETD2 loss and ATR inhibition synergize to promote cGAS signaling and immunotherapy response in renal cell carcinoma

Xian-De Liu

Abstract 44

Efficacy of immune checkpoint inhibitor (ICI) combination therapy as first-line (1L) treatment in metastatic renal cell carcinoma (mRCC).

Nikita Tripathi, MBBS

Abstract 47

Mapping the Distribution of Brain Metastases in Renal Cell Carcinoma (RCC) and Association with Clinical Features

Ardit Feinaj

Abstract 48

Novel inhibitor of pro-survival protein phosphatase 5 (PP5) leads to extrinsic apoptosis in VHL-null ccRCC

Rebecca A. Sager

Abstract 49

Dissecting metabolic alterations of clear cell renal cell carcinomas one cell at a time

Lucas A. Salas

Abstract 51

Characterization of FOLH1 Expression in Renal Cell Carcinoma

Eric Ovruchesky

Abstract 53

Vascular endothelial profilin-1 drives a pro-tumorigenic tumor microenvironment and tumor progression in renal cancer

David Gau

Abstract 54

PDL1 expression is inherently tied to the epithelial to mesenchymal transition in renal cell carcinoma: implications for immunotherapy

Allison May

Abstract 55

Evaluating the Clinical Utility of Circulating Tumor Cells (CTC) Profiling to Predict Selection of Preferred Therapeutic Regimens in Newly Diagnosed or Pretreated Refractory Renal Cell Carcinomas (RCC)

Ulka N. Vaishampayan

Abstract 56

Single Cell Spatial Analysis Identifies Enriched Transcriptomic and Spatial Patterns Among Immunotherapy Resistant Clear Cell Renal Cell Carcinoma Tumors

Alex Soupir

Abstract 57

Stratifying Patients Based on Abundance of Sarcomatoid Features Reveals Differential Transcriptomes and Survival Outcomes in Sarcomatoid Renal Cell Carcinoma

Nicholas Salgia

Abstract 60

89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma: Results from phase 3 ZIRCON study

Mary Jessel

Abstract 61

Statins inhibit metastases of kidney cancer by targeting the metastatic drivers, VHL(-) cells, and thus disrupting intratumoral communication

Moe Ishihara

Abstract 66

Characterization of Tumor Response With Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the CLEAR Study (4-Year Median Follow Up)

Robert J. Motzer

Abstract 67

TRAVERSE: A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)

Samer Srour

Abstract 69

Adjuvant Pembrolizumab for Renal Cell Carcinoma Across UCLA Integrated Staging System Risk Groups and Disease Stage: Subgroup Analyses From the KEYNOTE-564 Study

Toni Choueiri

Abstract 72

The “very favorable” metastatic Renal Cell Carcinoma (mRCC) risk group: data from the International mRCC Database Consortium (IMDC)

Valisha Shah

Abstract 79

Intratumoral heterogeneity of VHL and HIF1α drives lung metastasis in ccRCC

Junhui Hu

Abstract 82

In Pursuit of the IMDC: Turkish Oncology Group Kidney Cancer Consortium Database (TKCC)

Emre Yekedüz MD

Abstract 86

Identification of molecular vulnerabilities in aggressive renal cell carcinoma by a small molecule

Ara Jo

Abstract 89

Preclinical investigation of PSMA-based theranostics for renal cell Carcinoma

Sangeeta Ray

Abstract 90

Pathological Response and Outcomes of Patients with Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy after Immunotherapy Regimens

Damla Gunenc

Posters: Trials in Progress

Abstract 68

LITESPARK-024: Randomized Phase 1/2 Study of Belzutifan With or Without Palbociclib for Treatment of Advanced Renal Cell Carcinoma

David F. McDermott

Abstract 81

NRG-GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Rental Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

Rana R. McKay

Abstract 92

Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies

Eric Jonasch


Kidney Cancer Research Summit

July 13–14, 2023 – Boston, MA

Click the image above to download the Abstract Book.
Updated 07.03.23